• In early June 2026, Medtronic received FDA 510(k) clearance for its Nellcor pulse oximetry system with the Nell-EQ intelligent processor, aimed at delivering more consistent oxygen saturation and pulse rate monitoring across diverse skin tones and care settings.
• This clearance, aligned with new ISO standards and supported by prior Safer Technologies Program designation, strengthens Medtronic’s position in equitable patient monitoring and advanced acute care technologies.
• We’ll now examine how this new FDA-cleared, skin-tone-inclusive Nell-EQ pulse oximetry platform may reshape Medtronic’s broader investment narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 26 companies in the world exploring or producing it. Find the list for free.

Medtronic Investment Narrative Recap

To own Medtronic, you need to believe its broad device portfolio and steady innovation can compound value even if growth is not rapid. Near term, the key catalyst is execution on higher margin, tech-enabled platforms, while the biggest risk is continued gross margin pressure if new launches stumble or mix stays unfavorable. The Nell-EQ clearance itself does not materially change those drivers, but it reinforces Medtronic’s push into differentiated monitoring technologies.

Among recent announcements, the most relevant to Nell-EQ is Medtronic’s expanded U.S. distribution partnership with Corsano Health’s multi-parameter wearable. Together, these moves point to a broader acute care and remote monitoring ecosystem that could support higher value, recurring revenue over time. For investors, the question is whether this ecosystem meaningfully offsets underperformance in areas like U.S. Diabetes and parts of MedSurg and Neuroscience, where structural headwinds remain.

Yet behind these innovation wins, investors should also be aware of lingering concerns around margin pressure and execution on major new platform ramp ups...

Medtronic's narrative projects $40.7 billion revenue and $6.4 billion earnings by 2029. This requires 4.6% yearly revenue growth and about a $1.8 billion earnings increase from $4.6 billion today.

Uncover how Medtronic's forecasts yield a $105.76 fair value, a 32% upside to its current price.

Exploring Other Perspectives

The most pessimistic analysts were only assuming about 2 percent annual revenue growth to roughly US$38.6 billion and US$6.2 billion in earnings by 2029, so this new Nell-EQ news could ultimately shift how those expectations and the catheter ecosystem catalyst are viewed.

Explore 6 other fair value estimates on Medtronic - why the stock might be worth as much as 32% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Medtronic research is our analysis highlighting 6 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Medtronic research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Medtronic's overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.